Understanding GLP-1 signaling: A path to better therapies
Medical Xpress
February 27, 2026
About one in eight U.S. adults are currently taking a GLP-1 drug such as Ozempic, Wegovy, or Zepbound to treat diabetes, obesity, or other conditions, according to a KFF Health Tracking poll. But many suffer from significant side effects including nausea or vomiting. And for diabetic patients who also have conditions such as cancer or HIV, achieving glycemic control to effectively manage their blood sugar levels while avoiding weight or appetite loss is especially critical.
Verticals
healthmedical
Originally published on Medical Xpress on 2/27/2026